Fevipiprant Anti Hair Loss Powder 99% QAW039 Cas NO 872365-14-5 In Bulk
Place of Origin | China |
---|---|
Brand Name | XRD |
Certification | GMP |
Model Number | 872365-14-5 |
Minimum Order Quantity | negotiable |
Price | Inquiry for Negotiable |
Packaging Details | 1-2 kg / aluminum foil bag, 25kg/ drum, as required |
Delivery Time | 1-2days after payment received |
Payment Terms | T/T bank, Western Union, Bitcoin, Etc |
Supply Ability | 100KG/ Month |

Contact me for free samples and coupons.
Whatsapp:0086 18588475571
Wechat: 0086 18588475571
Skype: sales10@aixton.com
If you have any concern, we provide 24-hour online help.
xCAS | 872365-14-5 | Product Name | Fevipiprant |
---|---|---|---|
Type | Loss Hair | Appearance | White Powder |
Usage | Loss Hair | Alias | QAW039 |
Assay | 99% | Key Words | Fevipiprant |
High Light | hair growing powder,hair growth powder |
Fevipiprant powder 99% QAW039 Cas 872365-14-5 Powder in Bulk
Quick Details Name |
Fevipiprant |
Synonyms |
QAW 039; [1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid |
Brand |
Salus |
Molecular Formula |
C19H17F3N2O4S |
Molecular Weight |
426.41 |
CAS Registry Number |
872365-14-5 |
Description:
Fevipiprant is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). Its ability to extend the anagen (growing) phase of hair follicles. Although this won’t stop androgenic alopecia from progressing further, it will have the short term effect of making hair appear thicker. What’s more, this effect could make Setipiprant an effective treatment for the prevention of telogen effluvium. But perhaps the biggest advantage of Setipiprant is that is expected to have zero anti-androgenic effects.
Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelionwhich acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2).[1] It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients,[2][3] it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
Fevipiprant powder 99% QAW039 Cas 872365-14-5 Powder in Bulk